An Ebola vaccine, developed by a UTMB scientist and a Canadian collaborator, is moving to human trials more than a decade after it proved 100 percent effective in monkey trials. Thomas Geisbert of UTMB was at a conference in Germany in 2000 when he and a friend, Dr. Heinz Feldman of the Level 4 Containment Lab in Winnipeg, Canada, decided to work together on developing a vaccine against Ebola. Data from the study will help determine the dosage necessary to generate an effective immune response in patients, the key to setting production amounts that already are moving at record speed. "It feels good to see a thing that I have spent my whole career on doing some good," Geisbert said.